LM-24C5 / Sino Biopharm - LARVOL DELTA

A Study of LM-24C5 For Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=49 | Recruiting | Sponsor: LaNova Medicines Limited | Trial completion date: Mar 2026 ➔ Dec 2026 | Trial primary completion date: Jun 2025 ➔ Jun 2026

Trial completion date • Trial primary completion date • Solid Tumor

A Study of LM-24C5 For Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=49 | Recruiting | Sponsor: LaNova Medicines Limited | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

A Study of LM-24C5 For Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=49 | Not yet recruiting | Sponsor: LaNova Medicines Limited

Metastases • New P1/2 trial • Oncology • Solid Tumor

Pre-clinical efficacy and toxicity profile of LM-24C5: A novel CEACAM5 x 4-1BB bispecific antibody in cancer immunotherapy (AACR 2023) - "It induced superior 4-1BB activity (EC50: 1.07 nM) than benchmark antibody Urelumab (EC50: 3.38 nM) in the presence of cells expressing CEACAM5. LM-24C5 was well tolerated in hu4-1BB/4-1BBL double-transgenic mice at a dose of 100mg/kg given once weekly for 2 weeks. In summary, LM-24C5 is a novel CEACAM5 dependent 4-1BB bispecific agonist antibody that could redirect and activate T cells to CEACAM5 positive tumor cells by engaging 4-1BB antigen, thus positioned as a potential novel therapy for colorectal carcinoma and other CEACAM5 positive tumors."

IO biomarker • Preclinical • Colon Cancer • Colorectal Cancer • Embryonal Tumor • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD4 • CD8 • CEACAM5 • FCGR2A • IFNG